Learning objectives

1. The learner will be able to recognize the prevalence of hypertension and elevated blood pressure among youth.
2. The learner will be able to review proper diagnosis, management, and treatment of hypertension and elevated blood pressure among children and adolescents including medication management.
3. The learner will be able to evaluate the impact of the DASH diet on blood pressure control in youth and cardiovascular risk in young adulthood.
4. The learner will be able to define Pediatric Post-Intensive Care Syndrome
5. The learner will be able to Identify risk factors for Pediatric Post-Intensive Care Syndrome
6. The learner will be able to Identify tools available to screen patients for Pediatric Post-Intensive Care Syndrome
7. The learner will be able to analyze the evolving legal landscape governing Advanced Practice Providers (APPs), including Full Practice Authority (FPA) laws and their implications for professional liability and risk exposure.
8. The learner will be able to apply clinical risk identification strategies to common malpractice scenarios involving APPs, with emphasis on diagnostic reasoning, documentation, and telehealth limitations.
9. The learner will be able to evaluate the intersection of APP autonomy and accountability, using real-world case studies to explore how increased independence heightens both clinical responsibility and institutional oversight demands.
10. The learner will be able to Identify unique genetic challenges and cultural beliefs that create additional healthcare needs
11. The learner will be able to Identify unique circumstances in the Plain Community that increase their risk of trauma
12. The learner will be able to Identify ways in which personalized care is being provided to the Plain Community in Central Pennsylvania
13. The learner will be able to describe the scope of chemical proliferation since 1950 and its implications for pediatric health, referencing evidence from The Lancet Commission on Pollution and Health.
14. The learner will be able to Identify common sources and biological pathways of exposure for phthalates and parabens in children, including ingestion, inhalation, and dermal absorption routes.
15. The learner will be able to discuss current evidence linking phthalate and paraben exposure to pediatric endocrine, neurodevelopmental, and reproductive outcomes, and evaluate the need for improved research and policy measures to protect vulnerable populations.
16. The learner will be able to Identify key clinical features, diagnostic strategies, and treatment options for Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA), with a focus on emerging gene therapies such as Zolgensma and Elevidys.
17. The learner will be able to explore the complexities involved in pursuing novel treatments, including genetic testing, research protocols, and multidisciplinary coordination.
18. The learner will be able to discuss challenges related to clinical trials, transitioning therapies to commercial use, navigating insurance authorization, and understanding the financial impact on families.